Smooth Drug Development July 2026 News Release

News – July 2026

Throughout July, our clinical programs continued to make steady progress, supported by key regulatory submissions, active feasibility studies, and strategic partnerships across global regions.

Contracts for the following studies were signed:

·         A Phase III trial with Pertuzumab

·         A Phase I trial with Somatropin

·         A Phase I trial with Galsulfase

·         A BE trial with Tirzepatide.

Clinical and Scientific Departments News:

Phase I-IV Clinical Trials

·       A Phase III Gynecology Study: A total of 247 patients were screened, and 194 patients were randomized.

·       A Phase III Gynecology Study: A total of 29 patients were screened, and 23 patients were randomized.

·       A Phase IV HIV Study: Site selection is now complete, with 18 sites confirmed across the network. The study documentation has been submitted to the relevant authorities and is currently pending approval.

·       A Phase III HIV Study: Patient recruitment was successfully completed, with a total of 216 patients randomized.

·       A Phase IV Neurology Study: A total of 24 patients were included in the study.

·       A Phase I/II and III Breast Cancer Study: A total of 44 patients were screened, and 41 patients were randomized.

·       A Phase III Infectious Diseases (Hepatitis) Study:

In Georgia, local IRB approval was received.

In Uzbekistan, all regulatory approvals were granted, and import licenses were obtained.

2 Sites were initiated.

Bioequivalence (BE) Study

·       A Healthy Volunteers BE Study: A total of 62 subjects were randomized.

Business Development News:

Our Business Development team has been actively expanding partnerships and exploring new opportunities through strategic discussions and conference participation:

Key Partner Engagements

·       Our Pakistan team will attend the Clinical Trials Summit of Pakistan – 2nd Chapter, to be held at NUMS Rawalpindi, 3-4 Aug 2026. The team will engage with key stakeholders from the local clinical research community, including academic institutions, hospital networks, and regulatory representatives. The summit will serve as a valuable platform to showcase our clinical trial capabilities, discuss regional collaboration opportunities, and strengthen our presence in the Pakistani market.